National Institute of Advanced Industrial Science and Technology

Hokusan Co. Ltd

Idemitsu Kosan Company, Limited

Hokkaido University

School Juridical Person the Kitasato Institute

Noriko Tabayashi

Takeshi Matsumura

Akira Ito

Uiko Kagaya

Toru Gotanda

Noriko Itchoda

Takeshi Matsui

Kazutoshi Sawada

Eiji Takita

Rie Yasuno

Chihiro Sugimoto

Hiroko Miyashiro

Hanae Sasaki

Takashi Aoki

Hiromi Ikadai

It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.

Malaria transmission blocking vaccine

The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-&#x3b1; (IFN&#x3b1;) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN&#x3b1; can give a sufficient effect even when administered in a very small amount.

Therapeutic effect of oral interferon a administration on chronic intractable external otitis

The present invention provides an agent for controllingdiarrhea comprising a Shiga toxin as an active ingredient.

[object Object]

Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.

Adiponectin-containing eating behavior control agent for oral administration

Growing community of inventors

Kitahiroshima, Japan

Noriko Tabayashi